Sophie Viaud, Fabiana Saccheri, Grégoire Mignot, Takahiro Yamazaki, Romain Daillère, Dalil Hannani, David P Enot, Christina Pfirschke, Camilla Engblom, Mikael J Pittet, Andreas Schlitzer, Florent Ginhoux, Lionel Apetoh, Elisabeth Chachaty, Paul-Louis Woerther, Gérard Eberl, Marion Bérard, Chantal Ecobichon, Dominique Clermont, Chantal Bizet, Valérie Gaboriau-Routhiau, Nadine Cerf-Bensussan, Paule Opolon, Nadia Yessaad, Eric Vivier, Bernhard Ryffel, Charles O Elson, Joël Doré, Guido Kroemer, Patricia Lepage, Ivo Gomperts Boneca, François Ghiringhelli, Laurence Zitvogel
Cyclophosphamide is one of several clinically important cancer drugs whose therapeutic efficacy is due in part to their ability to stimulate antitumor immune responses. Studying mouse models, we demonstrate that cyclophosphamide alters the composition of microbiota in the small intestine and induces the translocation of selected species of Gram-positive bacteria into secondary lymphoid organs. There, these bacteria stimulate the generation of a specific subset of "pathogenic" T helper 17 (pT(H)17) cells and memory T(H)1 immune responses...
November 22, 2013: Science